BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

376 related articles for article (PubMed ID: 31449520)

  • 1. Increased vulnerability of nigral dopamine neurons after expansion of their axonal arborization size through D2 dopamine receptor conditional knockout.
    Giguère N; Delignat-Lavaud B; Herborg F; Voisin A; Li Y; Jacquemet V; Anand-Srivastava M; Gether U; Giros B; Trudeau LÉ
    PLoS Genet; 2019 Aug; 15(8):e1008352. PubMed ID: 31449520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative analysis of Parkinson's disease-associated genes in mice reveals altered survival and bioenergetics of Parkin-deficient dopamine neurons.
    Giguère N; Pacelli C; Saumure C; Bourque MJ; Matheoud D; Levesque D; Slack RS; Park DS; Trudeau LÉ
    J Biol Chem; 2018 Jun; 293(25):9580-9593. PubMed ID: 29700116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Age-dependent nigral dopaminergic neurodegeneration and α-synuclein accumulation in RGS6-deficient mice.
    Luo Z; Ahlers-Dannen KE; Spicer MM; Yang J; Alberico S; Stevens HE; Narayanan NS; Fisher RA
    JCI Insight; 2019 May; 5(13):. PubMed ID: 31120439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neonatal 6-OHDA lesion of the SNc induces striatal compensatory sprouting from surviving SNc dopaminergic neurons without VTA contribution.
    Tanguay W; Ducrot C; Giguère N; Bourque MJ; Trudeau LE
    Eur J Neurosci; 2021 Oct; 54(7):6618-6632. PubMed ID: 34470083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated Mitochondrial Bioenergetics and Axonal Arborization Size Are Key Contributors to the Vulnerability of Dopamine Neurons.
    Pacelli C; Giguère N; Bourque MJ; Lévesque M; Slack RS; Trudeau LÉ
    Curr Biol; 2015 Sep; 25(18):2349-60. PubMed ID: 26320949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease.
    Ahlers-Dannen KE; Spicer MM; Fisher RA
    Mol Pharmacol; 2020 Dec; 98(6):730-738. PubMed ID: 32015009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease.
    Liang CL; Wang TT; Luby-Phelps K; German DC
    Exp Neurol; 2007 Feb; 203(2):370-80. PubMed ID: 17010972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ghrelin on the motor deficit caused by the ablation of nigrostriatal dopaminergic cells or the inhibition of striatal dopamine receptors.
    Suda Y; Kuzumaki N; Narita M; Hamada Y; Shibasaki M; Tanaka K; Tamura H; Kawamura T; Kondo T; Yamanaka A; Narita M
    Biochem Biophys Res Commun; 2018 Feb; 496(4):1102-1108. PubMed ID: 29378186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential contribution of Ih to the integration of excitatory synaptic inputs in substantia nigra pars compacta and ventral tegmental area dopaminergic neurons.
    Masi A; Narducci R; Resta F; Carbone C; Kobayashi K; Mannaioni G
    Eur J Neurosci; 2015 Nov; 42(9):2699-706. PubMed ID: 26354486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does altering proteasomal activity and trafficking reduce the arborization mediated specific vulnerability of SNpc dopaminergic neurons of Parkinson's disease?
    Bhaskar S; Gowda J; Prasanna J; Kumar A
    Med Hypotheses; 2020 Oct; 143():110062. PubMed ID: 32652429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic methamphetamine-induced neurodegeneration: Differential vulnerability of ventral tegmental area and substantia nigra pars compacta dopamine neurons.
    Du Y; Lee YB; Graves SM
    Neuropharmacology; 2021 Dec; 200():108817. PubMed ID: 34610287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Morpho-Functional Changes of Nigral Dopamine Neurons in an α-Synuclein Model of Parkinson's Disease.
    Ledonne A; Massaro Cenere M; Paldino E; D'Angelo V; D'Addario SL; Casadei N; Nobili A; Berretta N; Fusco FR; Ventura R; Sancesario G; Guatteo E; Mercuri NB
    Mov Disord; 2023 Feb; 38(2):256-266. PubMed ID: 36350188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting microglial NLRP3 in the SNc region as a promising disease-modifying therapy for Parkinson's disease.
    Qiao C; Dang T; Zhou Y; Zhou YZ; Zhao R; Wang M
    Brain Behav; 2022 Nov; 12(11):e2784. PubMed ID: 36199191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implication of dopamine D3 receptor activation in the reversion of Parkinson's disease-related motivational deficits.
    Carnicella S; Drui G; Boulet S; Carcenac C; Favier M; Duran T; Savasta M
    Transl Psychiatry; 2014 Jun; 4(6):e401. PubMed ID: 24937095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role for VGLUT2 in selective vulnerability of midbrain dopamine neurons.
    Steinkellner T; Zell V; Farino ZJ; Sonders MS; Villeneuve M; Freyberg RJ; Przedborski S; Lu W; Freyberg Z; Hnasko TS
    J Clin Invest; 2018 Feb; 128(2):774-788. PubMed ID: 29337309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parkinson's Disease: Cells Succumbing to Lifelong Dopamine-Related Oxidative Stress and Other Bioenergetic Challenges.
    Watanabe H; Dijkstra JM; Nagatsu T
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Midbrain Gene Screening Identifies a New Mesoaccumbal Glutamatergic Pathway and a Marker for Dopamine Cells Neuroprotected in Parkinson's Disease.
    Viereckel T; Dumas S; Smith-Anttila CJ; Vlcek B; Bimpisidis Z; Lagerström MC; Konradsson-Geuken Å; Wallén-Mackenzie Å
    Sci Rep; 2016 Oct; 6():35203. PubMed ID: 27762319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adult Conditional Knockout of PGC-1α Leads to Loss of Dopamine Neurons.
    Jiang H; Kang SU; Zhang S; Karuppagounder S; Xu J; Lee YK; Kang BG; Lee Y; Zhang J; Pletnikova O; Troncoso JC; Pirooznia S; Andrabi SA; Dawson VL; Dawson TM
    eNeuro; 2016; 3(4):. PubMed ID: 27622213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of dopaminergic neuron loss in Parkinson's disease.
    Surmeier DJ
    FEBS J; 2018 Oct; 285(19):3657-3668. PubMed ID: 30028088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.